eHIV Review

Better tolerability. More convenient dosing. Less serious side effects. Fewer potential drug-drug interactions. These are some of the most common reasons why individuals living with HIV want or need to change their currently successful ART regimens. 

But what do clinicians need to consider when determining which ART to switch to? What role do the patient’s comorbidities play in the selection process? How do changes in the patient’s condition not related to HIV affect the safety and efficacy of their current regimen? What does the evidence say? 

Join us in this eHIV Review podcast for a case-based discussion with Dr. Natasha Chida, from the Division of Infectious Diseases at the Johns Hopkins University School of Medicine, about these increasingly important issues. 

• Summarize the role of comorbidities when evaluating a switch in ART regimens in individuals living with HIV who are virally suppressed on their current medications. 
• Describe the need to avoid drug-drug interactions when it becomes necessary to switch ART regimens in individuals living with HIV who are virally suppressed on their current medications.